证券代码：837023 证券简称：芭薇股份 公告编号：2025-010 广东芭薇生物科技股份有限公司 关于持股 5%以上股东权益变动触及 1%的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 法律责任。 广东芭薇生物科技股份有限公司（以下简称"公司"）接到持股 5%以上股东 广州云美产业投资合伙企业（有限合伙）通知，该股东于 2025 年 3 月 3 日至 3 月 4 日期间通过集中竞价交易方式合计减持公司无限售条件流通股 434,519 股，占公司 总股本的 0.51%。 本次权益变动前，广州云美产业投资合伙企业（有限合伙）持有公司 7,142,857 股，占公司总股本的比例为 8.33%；本次权益变动后，广州云美产业投资合伙企业 （有限合伙）持有公司 6,708,338 股，占公司总股本的比例由 8.33%减少至 7.82%， 权益变动触及 1%整数倍的情形。现将具体情况公告如下： 三、所涉后续事项 （一）本次权益变动不会导致公司控股股东及实际控制人发生变化，不会对公 司生产经营产生不利影响； | ...

Investment Rating - The report maintains a "Recommended" investment rating for the company Bawei Co., Ltd. (837023.BJ) [1] Core Views - The company's revenue continues to grow rapidly due to the effectiveness of its major customer and single product strategy, achieving a revenue of 695 million yuan in 2024, a year-on-year increase of 48.24% [3][4] - The net profit attributable to shareholders for 2024 is projected to be 45.73 million yuan, reflecting a year-on-year growth of 11.11% [4] - The company is focusing on optimizing its customer and product structure to improve its gross margin, which has been affected by changes in its client base [3] - The cosmetics contract manufacturing industry is expanding, and the company is well-positioned to increase its market share by leveraging its strong R&D capabilities and supply chain management [3] Financial Performance Summary - **Revenue Forecast**: - 2024: 695 million yuan (up 48.24%) - 2025: 861 million yuan (up 23.97%) - 2026: 988 million yuan (up 14.67%) [4][7] - **Net Profit Forecast**: - 2024: 45.73 million yuan (up 11.11%) - 2025: 60.25 million yuan (up 31.74%) - 2026: 74.55 million yuan (up 23.74%) [4][7] - **Earnings Per Share (EPS)**: - 2024: 0.53 yuan - 2025: 0.70 yuan - 2026: 0.87 yuan [4][7] - **Price-to-Earnings (P/E) Ratio**: - 2024: 32.59 - 2025: 24.74 - 2026: 19.99 [4][7] Industry Outlook - The cosmetics industry is experiencing rapid growth driven by increasing consumer spending power, and the contract manufacturing segment is expected to see higher concentration as companies focus on maximizing profits [3] - The company aims to expand its production capacity and enhance its competitive edge through a comprehensive quality control system and a robust supply chain [3]

一、股票交易异常波动的具体情况 公司股票最近 2 个有成交的交易日（2025 年 2 月 28 日至 2025 年 3 月 3 日）以内收盘 价涨幅偏离值累计达到 41.27%，根据《北京证券交易所交易规则（试行）》的有关规定，属 于股票交易异常波动情形。 证券代码：837023 证券简称:芭薇股份 公告编号：2025-009 广东芭薇生物科技股份有限公司股票交易异常波动公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 三、是否存在应披露而未披露的重大信息的声明 本公司董事会确认，本公司没有任何根据《北京证券交易所股票上市规则（试行）》等 有关规定应披露而未披露的事项或与该事项有关的筹划、商谈、意向、协议等，董事会也未 获悉本公司有根据《北京证券交易所股票上市规则（试行）》等有关规定应披露而未披露的、 对本公司股票交易价格产生较大影响的信息。 四、公司及控股股东、实际控制人、董监高在异常波动期间交易公司股票的情况 公司及控股股东、实际控制人、董监高在异常波动期间不存在交易公司股票的情况。 二、公司关注 ...

Investment Rating - The report maintains a "Buy" rating for the company [2][8] Core Insights - The company reported a 48.2% year-on-year increase in revenue for 2024, reaching 695 million yuan, with a net profit of 45.73 million yuan, reflecting an 11.1% increase [5][8] - The company is focusing on functional skincare products, leveraging strong operational capabilities and partnerships with major brands, resulting in over 1,155 brand clients served by the end of 2024 [8] - The company is expanding its global presence, having established a factory in Indonesia and partnered with over 50 overseas brands, exporting more than 1,000 SKUs to 29 countries [8] - The company has made significant innovations, publishing 10 papers and applying for 29 patents in 2024, with a total of over 130 patents obtained [8] - The company is implementing an AI system based on DeepSeek to enhance supply chain efficiency and overall business intelligence [8] - The profit forecast for 2024 has been slightly adjusted upwards, with expected net profits of 46 million yuan for 2024, 80 million yuan for 2025, and 95 million yuan for 2026 [8] Financial Data and Profit Forecast - The total revenue is projected to grow from 469 million yuan in 2023 to 1,146 million yuan by 2026, with a compound annual growth rate of 13.6% [7][10] - The net profit is expected to increase from 41 million yuan in 2023 to 95 million yuan in 2026, with a significant growth rate of 18.7% in 2026 [7][10] - The company's gross margin is expected to improve from 28.2% in 2024 to 31.1% in 2026 [7]

Investment Rating - The investment rating for the company is "Outperform" (maintained) [2] Core Views - The company is expected to achieve a 15% year-on-year growth in net profit excluding non-recurring items in 2024, driven by a focus on major clients and flagship products amidst the domestic beauty wave [4][5] - The company reported a revenue of 695 million yuan in 2024, representing a 48.24% year-on-year increase, and a net profit attributable to the parent company of 45.73 million yuan, up 11.10% year-on-year [4] - The company is recognized as a leading player in the ODM (Original Design Manufacturer) segment of skincare products, with strong detection capabilities and growth potential [4][6] Financial Summary - Revenue is projected to grow from 469 million yuan in 2023 to 695 million yuan in 2024, with a year-on-year growth rate of 48.2% [7] - Net profit attributable to the parent company is expected to increase from 41 million yuan in 2023 to 46 million yuan in 2024, reflecting a growth rate of 11.4% [7] - The gross margin is forecasted to decline from 33.2% in 2023 to 28.4% in 2024, while the net margin is expected to decrease from 8.8% to 6.6% [7] - Earnings per share (EPS) are projected to rise from 0.48 yuan in 2023 to 0.53 yuan in 2024 [7] Strategic Initiatives - The company is actively expanding its domestic and international markets while implementing a strategy focused on major clients and flagship products [5] - The company has initiated the deployment of an AI system based on the DeepSeek model, marking a significant shift towards digital transformation [5] - The company aims to promote its own brand in foreign trade, leveraging its strong R&D and delivery capabilities [6]

Investment Rating - The investment rating for the company is "Outperform" (maintained) [2][4]. Core Insights - The company is expected to achieve a 15% year-on-year growth in net profit excluding non-recurring items in 2024, driven by a focus on major clients and flagship products amidst the domestic beauty wave [4][5]. - The company reported a revenue of 695 million yuan for 2024, representing a 48.24% year-on-year increase, and a net profit attributable to the parent company of 45.73 million yuan, up 11.10% year-on-year [4][7]. - The company is transitioning towards a digital strategy empowered by AI, with the initial deployment of an AI system based on the DeepSeek model [5][6]. Financial Summary - Revenue is projected to grow from 469 million yuan in 2023 to 695 million yuan in 2024, and further to 966 million yuan in 2025 [7][11]. - The net profit attributable to the parent company is expected to increase from 41 million yuan in 2023 to 46 million yuan in 2024, and reach 76 million yuan in 2025 [7][11]. - The gross margin is forecasted to decline slightly from 33.2% in 2023 to 28.4% in 2024, before recovering to 30.0% in 2025 [7][12]. - The company’s earnings per share (EPS) are projected to rise from 0.48 yuan in 2023 to 0.53 yuan in 2024, and further to 0.89 yuan in 2025 [7][11]. Strategic Initiatives - The company is actively expanding its domestic and international market presence while implementing a large client and large product strategy [5][6]. - The company has been recognized as the "Most Influential ODM Company of the Year" at the CiE Beauty Innovation Awards, highlighting its strong market position and innovative product offerings [6].

证券代码：837023 证券简称：芭薇股份 公告编号：2025-007 广东芭薇生物科技股份有限公司 关于审计机构变更项目质量控制复核人的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 法律责任。 广东芭薇生物科技股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召 开第三届董事会第二十七次会议、第三届监事会第十七次会议，审议通过了《关于 续聘天职国际会计师事务所（特殊普通合伙）为公司 2024 年度财务审计机构的议案》， 同意继续聘请天职国际会计师事务所（特殊普通合伙）为公司 2024 年度审计机构， 该议案已于 2024 年 5 月 20 日经公司 2023 年年度股东大会审议通过。 二、本次变更后项目质量复核人员的情况 1.基本信息 项目质量控制复核人叶慧，2006 年成为注册会计师，2007 年开始从事上市公司 审计，2006 年开始在天职国际会计师事务所（特殊普通合伙）执业，2024 年开始为 本公司提供审计服务，近三年签署上市公司审计报告 3 家，近三年复核上市公司审 计报告 3 ...

Financial Performance - The company achieved operating revenue of 694,746,074.26 yuan, representing a year-on-year increase of 48.24%[4] - Net profit attributable to shareholders was 45,726,795.81 yuan, up 11.10% compared to the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 41,685,694.92 yuan, reflecting a growth of 15.10%[4] - Basic earnings per share decreased by 1.85% to 0.53 yuan[4] - Total assets at the end of the reporting period were 837,184,219.24 yuan, an increase of 26.24% year-on-year[4] - Shareholders' equity attributable to the company was 400,260,417.46 yuan, up 22.33% from the previous year[4] Strategic Focus - The company's strategy focused on deepening research and development in cosmetics and expanding both domestic and international markets, contributing to revenue growth[6] - The decline in net profit growth compared to revenue growth was primarily due to changes in customer and product structure, leading to a decrease in gross margin[6] - The company plans to continue investing in smart manufacturing to support rapid order fulfillment and maintain a focus on major clients and products[6] Outlook and Guidance - The company's earnings guidance indicates a cautious outlook due to the preliminary nature of the financial data, which has not yet been audited[7]

证券代码：837023 证券简称：芭薇股份 公告编号：2025-006 广东芭薇生物科技股份有限公司 关于注销部分募集资金专项账户的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 法律责任。 一、募集资金基本情况 2024 年 2 月 22 日，中国证券监督管理委员会做出《关于同意广东芭薇生物科 技股份有限公司向不特定合格投资者公开发行股票注册的批复》（证监许可〔2024〕 322 号），同意广东芭薇生物科技股份有限公司（以下简称"公司"）向不特定合 格投资者公开发行股票的注册申请，公司于 2024 年 3 月 29 日上市。 三、本次募集资金专项账户注销情况 鉴 于 公 司 在 招 商 银 行 股 份 有 限 公 司 广 州 机 场 路 支 行 （ 银 行 账 号 ： 120911782110001）开立的"智能生产车间建设项目"募集资金专项账户中存放的 募集资金已按计划使用完毕，为便于管理，公司将该募集资金专户余额 115.16 元转 入公司基本户，用于补充日常经营流动资金，并申请办理注销该募集资金专项账 ...

证券代码：837023 证券简称：芭薇股份 公告编号：2025-005 √是 □否 上述股东拟在本次公告 15 个交易日后 3 个月内通过集中竞价方式合计卖出 公司股份总数可能超过公司股份总数的 1%。 广东芭薇生物科技股份有限公司 持股 5%以上股东减持股份的预披露公告（再次披露） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、减持主体的基本情况 | 股东名称 | 股东身份 | | 持股数量（股） | 持股比例 | 当前持股股份来源 | | --- | --- | --- | --- | --- | --- | | 广州云美产 | | | | | | | 业投资合伙 | 持股 | 5%以上 | 7,142,857 | 8.33% | 北京证券交易所上 | | 企业（有限 | | 股东 | | | 市前取得 | | 合伙） | | | | | | 二、减持计划的主要内容 | 股东 | 计划减持 | 计划减 | 减持 | 减持 | 减持价 | 拟减持股 | 拟减持 | | --- | --- | - ...